title: Fetal hemoglobin level and nutritional status in patients with sickle cell disease.
abstract: Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients' nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.
authors.affiliation: Department of Pediatrics, Division of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine at Northwestern University, 225 E Chicago Ave., Box # 30, Chicago, IL, 60611, USA. sbadawy@luriechildrens.org.|Department of Pediatrics, Division of Hematology/Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. sbadawy@luriechildrens.org.
authors.forename: Sherif M
authors.initials: SM
authors.lastname: Badawy
mesh_terms: D000755:Anemia, Sickle Cell; D005319:Fetal Hemoglobin / Q000032:analysis*; D006801:Humans; D006918:Hydroxyurea; D009752:Nutritional Status
chemical_list: D005319:Fetal Hemoglobin; D006918:Hydroxyurea
keywords: Fetal hemoglobin; Hydroxyurea; Nutrition; Sickle cell disease